Citi Bearish On Dr Reddy's; CLSA Positive On HAL, Says Company Has Strongest Pipeline Of Orders
•February 25, 2026
0
Why It Matters
Citi’s caution signals potential earnings pressure for Dr Reddy’s, whereas CLSA’s optimism points to robust growth and cash flow stability for HAL, influencing investor allocation between pharma and aerospace sectors.
Key Takeaways
- •Citi doubts Dr Reddy's generic semaglutide upside
- •CLSA rates HAL as preferred with robust order pipeline
- •HAL holds 14-year order backlog, boosting revenue visibility
- •Dr Reddy's faces competitive pressure in GLP‑1 market
- •Investors may favor HAL over pharma amid growth prospects
Pulse Analysis
The generics market for GLP‑1 therapies, especially semaglutide, has become a battleground as multiple manufacturers vie for a share of a high‑margin segment. Citi’s bearish outlook on Dr Reddy’s reflects skepticism about the company’s ability to achieve cost‑effective scale and navigate patent hurdles that could limit pricing power. Analysts also point to the rapid entry of competitors from both domestic and international pools, which may compress margins and delay revenue ramp‑up for any new generic entrant.
Conversely, Hindustan Aeronautics Limited is riding a wave of sustained demand driven by India’s defense modernization agenda. CLSA’s endorsement underscores HAL’s deep order book, anchored by a 14‑year backlog that includes fighter aircraft, helicopters, and aerospace components. This long‑term visibility reduces earnings volatility and positions HAL to benefit from government spending cycles, foreign‑partner collaborations, and potential export opportunities. The company’s diversified product mix further cushions it against sector‑specific shocks.
For investors, the juxtaposition of these two analyst calls highlights a broader sector rotation narrative. While pharma faces pricing pressure and regulatory uncertainty, aerospace enjoys a quasi‑monopolistic supply chain tied to national security priorities. Portfolio managers may therefore tilt toward assets with predictable cash flows, such as HAL, while remaining cautious on pharma stocks like Dr Reddy’s that depend on successful generic launches in a crowded market. Understanding these dynamics is crucial for strategic allocation in a volatile macro environment.
Original Description
Brokerage Call Of The Day
Citi View on Dr Reddys
- Cautious on generic Semaglutide potential for Dr Reddy’s
CLSA on Hinudustan Aeronautics
- Preferred pick; Strongest pipeline of orders & 14 years of backlog
Sudarshan Kumar with the details.
#brokeragereport #drreddyslaboratories #hindustanaeronautics #citi #clsa #cnbctv18 #cnbctv18market #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday
🔴CNBC TV18 LIVE TV: https://youtube.com/live/P857H4ej-MQ
SUBSCRIBE to our Channel: https://bit.ly/3nvEcxf
---------------------------------------------------------------------------------------------------------------------
👑 Check Out Top CNBC TV18 Playlist Videos:
------------------------------------------------------------------------------------
You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM
Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/
Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/
You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/
Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News
Follow us on Instagram: https://www.instagram.com/cnbctv18india/
Catch us on: Linkedin: https://in.linkedin.com/company/cnbc-tv18
n18oc_business
About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here.
0
Comments
Want to join the conversation?
Loading comments...